Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Jochen Klaus Maria Lennerz, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Jochen Lennerz and Justin Gainor.
Connection Strength

1.850
  1. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clin Cancer Res. 2021 Mar 08.
    View in: PubMed
    Score: 0.247
  2. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol. 2020 12; 31(12):1725-1733.
    View in: PubMed
    Score: 0.240
  3. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.206
  4. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.199
  5. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133.
    View in: PubMed
    Score: 0.179
  6. Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification. J Thorac Oncol. 2016 07; 11(7):e83-5.
    View in: PubMed
    Score: 0.175
  7. Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 2021 Apr 06.
    View in: PubMed
    Score: 0.062
  8. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. J Thorac Oncol. 2021 May; 16(5):850-859.
    View in: PubMed
    Score: 0.061
  9. Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. NPJ Precis Oncol. 2020; 4:21.
    View in: PubMed
    Score: 0.059
  10. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clin Cancer Res. 2020 06 01; 26(11):2535-2545.
    View in: PubMed
    Score: 0.057
  11. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer. Clin Lung Cancer. 2020 03; 21(2):153-159.e3.
    View in: PubMed
    Score: 0.056
  12. Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. Clin Cancer Res. 2019 11 15; 25(22):6662-6670.
    View in: PubMed
    Score: 0.055
  13. Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. J Thorac Oncol. 2019 05; 14(5):816-824.
    View in: PubMed
    Score: 0.053
  14. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539.
    View in: PubMed
    Score: 0.052
  15. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. J Thorac Oncol. 2018 10; 13(10):1530-1538.
    View in: PubMed
    Score: 0.051
  16. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 06; 8(6):714-729.
    View in: PubMed
    Score: 0.050
  17. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 05; 12(5):872-877.
    View in: PubMed
    Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.